Elyxium Wealth’s Telix Pharmaceuticals TLX Stock Holding History

Elyxium Wealth’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$132	Buy	+12	New	+$136	﹤0.01%	1456

Other funds holding TLX

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return

WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return

Aspect Partners Fairfax, Virginia $264M AUM 15.76% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Elyxium Wealth's TLX Position: Q3 2026 in Review

Elyxium Wealth opened a new position in Telix Pharmaceuticals (TLX) in Q3 2026: 12 shares worth $132. The stake represents ﹤0.01% of the portfolio and ranks #1456 among its holdings.

15 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

Elyxium Wealth held 12 shares of Telix Pharmaceuticals worth $132 as of Q3 2026.
Telix Pharmaceuticals was a new Elyxium Wealth position in Q3 2026.
Telix Pharmaceuticals made up ﹤0.01% of Elyxium Wealth's portfolio in Q3 2026, its #1456 holding.
15 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on Elyxium Wealth's 13F filing for Q3 2026, filed 27 Oct 2026.